Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
86 participants
INTERVENTIONAL
2009-09-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility
NCT05222841
Male Supplements for Sperm Quality and Aging
NCT06339996
Power Prenatal Supplements for Sperm Quality
NCT05410782
Is a Carnitine Based Food Supplement (PorimoreTM) for Infertile Men Superior to Folate and Zinc With Regard to Pregnancy Rates in Intrauterine Insemination Cycles?
NCT01075334
Supplement Intake in Infertile Men;the Effect on Sperm Parameters,Fertilization Rate and Embryo Quality
NCT01520584
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
One Placebo tablet (Orally administered) twice a day, for 12 weeks.
Spermotrend
Spermotrend
One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
One Placebo tablet (Orally administered) twice a day, for 12 weeks.
Spermotrend
One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have at least one altered seminal parameter.
* Signed informed consent
Exclusion Criteria
* Previously treated and cured testicular condition.
* Non-transmissible chronic diseases
* Use of antioxidant agents within 6 months.
* Use of vitamins within 6 months.
* Use of anti-inflammatory drugs within 6 months.
* Use of hormones prescribed by an andrologist within 6 months
* Positive serology/HIV
* Leukocytospermia
19 Years
60 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catalysis SL
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
"Ramón González Coro" Gynecologic and Obstetric Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Miguel Aguilar Charara, MD
Role: PRINCIPAL_INVESTIGATOR
"Ramón González Coro" Gynecologic and Obstetric Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
"Ramón González Coro" Gynecologic and Obstetric Hospital
Havana, La Habana, Cuba
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
de Ligny W, Smits RM, Mackenzie-Proctor R, Jordan V, Fleischer K, de Bruin JP, Showell MG. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2022 May 4;5(5):CD007411. doi: 10.1002/14651858.CD007411.pub5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAT-0905-CU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.